DOCSLIB.ORG

Refinement of the Docking Component of Virtual Screening for Pparγ Therapeutics Using Pharmacophore Analysis and Molecular Dynamics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Refinement of the Docking Component of Virtual Screening for Pparγ Therapeutics Using Pharmacophore Analysis and Molecular Dynamics Refinement of the Docking Component of Virtual Screening for PPARγ Therapeutics Using Pharmacophore Analysis and Molecular Dynamics Stephanie Nicole Lewis Dissertation submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Genetics, Bioinformatics, and Computational Biology David R. Bevan, Chair Josep Bassaganya-Riera Jill Sible Liqing Zhang June 11, 2013 Blacksburg, VA Keywords: Virtual screening, PPARγ, Drug discovery, Molecular docking, Pharmacophore screening, Molecular dynamics Copyright 2013, Stephanie Nicole Lewis Refinement of the Docking Component of Virtual Screening for PPARγ Therapeutics Using Pharmacophore Analysis and Molecular Dynamics Stephanie Nicole Lewis ABSTRACT Exploration of peroxisome proliferator-activated receptor-gamma (PPARγ) as a drug target holds applications for treating a wide variety of chronic inflammation-related diseases. Type 2 diabetes (T2D), which is a metabolic disease influenced by chronic inflammation, is quickly reaching epidemic proportions. Although some treatments are available to control T2D, more efficacious compounds with fewer side effects are in great demand. Drugs targeting PPARγ typically are compounds that function as agonists toward this receptor, which means they bind to and activate the protein. Identifying compounds that bind to PPARγ (i.e. binders) using computational docking methods has proven difficult given the large binding cavity of the protein, which yields a large target area and variations in ligand positions within the binding site. We applied a combined computational and experimental concept for characterizing PPARγ and identifying binders. The goal was to establish a time- and cost-effective way to screen a large, diverse compound database potentially containing natural and synthetic compounds for PPARγ agonists that are more efficacious and safer than currently available T2D treatments. The computational molecular modeling methods used include molecular docking, molecular dynamics, steered molecular dynamics, and structure- and ligand- based pharmacophore modeling. Potential binders identified in the computational component funnel into wet-lab experiments to confirm binding, assess activation, and test preclinical efficacy in a mouse model for T2D and other chronic inflammation diseases. The initial process used provided α-eleostearic acid as a compound that ameliorates inflammatory bowel disease in a pre-clinical trial. Incorporating pharmacophore analyses and binding interaction information improved the method for use with a diverse ligand database of thousands of compounds. The adjusted methods showed enrichment for full agonist binder identification. Identifying lead compounds using our method would be an efficient means of addressing the need for alternative T2D treatments. DEDICATION I would like to dedicate this dissertation to all the people in my life, both family and friends, who have done everything humanly possible to help me achieve my goals. Among those are most notably my mother, Stephanie R. Lewis, my grandmother, Bessie White, my husband, Steve Huff, our son, Ayden James, and my brothers, Darin and Daniel Lewis. Thank you for being my daily cheerleaders, entertainers, and taking pride in everything about me including my shortcomings. To my best friend and soul sister, Adria Markowski, thank you for taking the PhD journey with me, and showing me that greatness can be both dreamed and achieved. Thank you to Dennie Munson for being my mom away from home and my champion in all things academic. Thank you to my advisor, David Bevan, for seeing greatness in me, and allowing a level of freedom and independence that seems far too uncommon, but highly necessary, in graduate level education. Your confidence in me has truly helped my development as a leader, mentor, and scientist. Thank you to my amazing colleagues in the Bevan lab for being exceptional sounding boards for ideas, both great and not so great. Thank you to my graduate committee for constantly challenging my thought process and conclusions, and the PREP/IMSD faculty for facilitating professional guidance. The conversations with each of you have shaped my development as a researcher and guided me toward high-impact scientific thought. Thank you to all the students with whom I have worked while at Virginia Tech. It is through you that I see great potential and promise in the scientific endeavors to come. Lastly, I dedicate this to those who did not believe I could rise to this level of success. Through their lack of faith for various reasons at various times, I have been motivated to exceptional belief in my abilities and myself. iii ACKNOWLEDGEMENTS I would like to acknowledge and thank the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) for funding through the Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research (1F31DK091186-01A1). I would like to acknowledge and thank the VT-PREP and IMSD programs and the faculty of the program for their financial and developmental support. These programs are funded through NIH: Biomedical and Behavioral Sciences Research Training Grant R25 GM072767 (Virginia Tech Initiative to Maximize Student Diversity) and Grant R25 GM066534 (Virginia Tech Post Baccalaureate Research and Education Program). Additional sources responsible for funding of the experimental component were Grant 5R01AT4308 from the National Center for Complementary and Alternative Medicine and The National Institute for Allergy and Infectious Diseases Contract HHSN272201000056C. iv Table of Contents 1 Introduction ................................................................................................................. 1 1.1 Chronic inflammation .......................................................................................... 1 1.1.1 Type 2 diabetes ............................................................................................. 1 1.1.2 Inflammatory bowel disease ......................................................................... 2 1.2 PPARγ .................................................................................................................. 3 1.3 Motivation for dissertation project ....................................................................... 3 1.4 Organization of the dissertation ........................................................................... 4 2 Virtual screening as a technique for PPAR modulator discovery............................... 5 2.1 Abstract ................................................................................................................ 6 2.2 Introduction .......................................................................................................... 7 2.3 Characteristics of PPARγ and the activation process........................................... 7 2.4 Agonists and the ligand-binding domain of PPARγ ............................................ 9 2.5 Docking .............................................................................................................. 12 2.6 Virtual screening ................................................................................................ 13 2.7 Limitations of virtual screening ......................................................................... 14 2.8 Docking and virtual screening successes ........................................................... 15 2.9 Relevance to PPARγ agonist discovery ............................................................. 15 2.10 Future directions ............................................................................................. 16 2.11 Acknowledgements ........................................................................................ 17 3 Dietary -eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor- ..................................... 18 3.1 Abstract .............................................................................................................. 19 3.2 Introduction ........................................................................................................ 20 3.3 Methods .............................................................................................................. 21 3.3.1 Docking procedure ...................................................................................... 21 3.3.2 Structural model selection: Re-docking component ................................... 22 3.3.3 Structural model selection: Cross-docking component .............................. 22 3.3.4 Small-scale in-house ligand library construction ........................................ 23 3.3.5 Docking analysis for re-docking and cross-docking ................................... 23 3.3.6 Docking analysis for small-scale VS .......................................................... 24 3.3.7 Ligand binding assay .................................................................................. 24 3.3.8 Transfection of RAW 264.7 cells ............................................................... 25 3.3.9 Animal procedures ...................................................................................... 25 3.3.10 Histopathology ...........................................................................................
Load more

Recommended publications
  • Punicic Acid Triggers Ferroptotic Cell Death in Carcinoma Cells
    nutrients Article Punicic Acid Triggers Ferroptotic Cell Death in Carcinoma Cells Perrine Vermonden 1, Matthias Vancoppenolle 1, Emeline Dierge 1,2, Eric Mignolet 1,Géraldine Cuvelier 1, Bernard Knoops 1, Melissa Page 1, Cathy Debier 1, Olivier Feron 2,† and Yvan Larondelle 1,*,† 1 Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Croix du Sud 4-5/L7.07.03, B-1348 Louvain-la-Neuve, Belgium; [email protected] (P.V.); [email protected] (M.V.); [email protected] (E.D.); [email protected] (E.M.); [email protected] (G.C.); [email protected] (B.K.); [email protected] (M.P.); [email protected] (C.D.) 2 Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, 57 Avenue Hippocrate B1.57.04, B-1200 Brussels, Belgium; [email protected] * Correspondence: [email protected]; Tel.: +32-478449925 † These authors contributed equally to this work. Abstract: Plant-derived conjugated linolenic acids (CLnA) have been widely studied for their pre- ventive and therapeutic properties against diverse diseases such as cancer. In particular, punicic acid (PunA), a conjugated linolenic acid isomer (C18:3 c9t11c13) present at up to 83% in pomegranate seed oil, has been shown to exert anti-cancer effects, although the mechanism behind its cytotoxicity remains unclear. Ferroptosis, a cell death triggered by an overwhelming accumulation of lipid perox- ides, has recently arisen as a potential mechanism underlying CLnA cytotoxicity. In the present study, we show that PunA is highly cytotoxic to HCT-116 colorectal and FaDu hypopharyngeal carcinoma cells grown either in monolayers or as three-dimensional spheroids.
    [Show full text]
  • Open Babel Documentation Release 2.3.1
    Open Babel Documentation Release 2.3.1 Geoffrey R Hutchison Chris Morley Craig James Chris Swain Hans De Winter Tim Vandermeersch Noel M O’Boyle (Ed.) December 05, 2011 Contents 1 Introduction 3 1.1 Goals of the Open Babel project ..................................... 3 1.2 Frequently Asked Questions ....................................... 4 1.3 Thanks .................................................. 7 2 Install Open Babel 9 2.1 Install a binary package ......................................... 9 2.2 Compiling Open Babel .......................................... 9 3 obabel and babel - Convert, Filter and Manipulate Chemical Data 17 3.1 Synopsis ................................................. 17 3.2 Options .................................................. 17 3.3 Examples ................................................. 19 3.4 Differences between babel and obabel .................................. 21 3.5 Format Options .............................................. 22 3.6 Append property values to the title .................................... 22 3.7 Filtering molecules from a multimolecule file .............................. 22 3.8 Substructure and similarity searching .................................. 25 3.9 Sorting molecules ............................................ 25 3.10 Remove duplicate molecules ....................................... 25 3.11 Aliases for chemical groups ....................................... 26 4 The Open Babel GUI 29 4.1 Basic operation .............................................. 29 4.2 Options .................................................
    [Show full text]
  • Dietary Pomegranate Pulp to Improve Meat Fatty Acid Composition in Lambs
    Dietary pomegranate pulp to improve meat fatty acid composition in lambs Natalello A., Luciano G., Morbidini L., Priolo A., Biondi L., Pauselli M., Lanza M., Valenti B. in Ruiz R. (ed.), López-Francos A. (ed.), López Marco L. (ed.). Innovation for sustainability in sheep and goats Zaragoza : CIHEAM Options Méditerranéennes : Série A. Séminaires Méditerranéens; n. 123 2019 pages 173-176 Article available on line / Article disponible en ligne à l’adresse : -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ http://om.ciheam.org/article.php?IDPDF=00007880 -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ To cite this article / Pour citer cet article -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ Natalello A., Luciano G., Morbidini L., Priolo A., Biondi L., Pauselli M., Lanza M., Valenti B. Dietary pomegranate pulp to improve meat fatty acid composition in lambs. In : Ruiz R. (ed.), López- Francos A. (ed.), López Marco L. (ed.). Innovation for sustainability in sheep and goats. Zaragoza : CIHEAM, 2019. p. 173-176 (Options Méditerranéennes : Série A. Séminaires Méditerranéens; n. 123) --------------------------------------------------------------------------------------------------------------------------------
    [Show full text]
  • Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
    AEGAEUM JOURNAL ISSN NO: 0776-3808 Dualism of Peroxisome Proliferator-Activated Receptor α/γ: A Potent Clincher in Insulin Resistance Mr. Ravikumar R. Thakar1 and Dr. Nilesh J. Patel1* 1Faculty of Pharmacy, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Gujarat, India. [email protected] Abstract: Diabetes mellitus is clinical syndrome which is signalised by augmenting level of sugar in blood stream, which produced through lacking of insulin level and defective insulin activity or both. As per worldwide epidemiology data suggested that the numbers of people with T2DM living in developing countries is increasing with 80% of people with T2DM. Peroxisome proliferator-activated receptors are a family of ligand-activated transcription factors; modulate the expression of many genes. PPARs have three isoforms namely PPARα, PPARβ/δ and PPARγ that play a central role in regulating glucose, lipid and cholesterol metabolism where imbalance can lead to obesity, T2DM and CV ailments. It have pathogenic role in diabetes. PPARα is regulates the metabolism of lipids, carbohydrates, and amino acids, activated by ligands such as polyunsaturated fatty acids, and drugs used as Lipid lowering agents. PPAR β/δ could envision as a therapeutic option for the correction of diabetes and a variety of inflammatory conditions. PPARγ is well categorized, an element of the PPARs, also pharmacological effective as an insulin resistance lowering agents, are used as a remedy for insulin resistance integrated with type- 2 diabetes mellitus. There are mechanistic role of PPARα, PPARβ/δ and PPARγ in diabetes mellitus and insulin resistance. From mechanistic way, it revealed that dual PPAR-α/γ agonist play important role in regulating both lipids as well as glycemic levels with essential safety issues.
    [Show full text]
  • Toxicology Reports
    Antioxidant effect of pomegranate against streptozotocin- nicotinamide generated oxidative stress induced diabetic rats Author Aboonabi, Anahita, Rahmat, Asmah, Othman, Fauziah Published 2014 Journal Title Toxicology Reports Version Version of Record (VoR) DOI https://doi.org/10.1016/j.toxrep.2014.10.022 Copyright Statement © 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). Downloaded from http://hdl.handle.net/10072/142319 Griffith Research Online https://research-repository.griffith.edu.au Toxicology Reports 1 (2014) 915–922 Contents lists available at ScienceDirect Toxicology Reports journa l homepage: www.elsevier.com/locate/toxrep Antioxidant effect of pomegranate against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats a,∗ a,1 b,2 Anahita Aboonabi , Asmah Rahmat , Fauziah Othman a Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia b Department of Human Anatomy, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia a r t a b i c s t l e i n f o r a c t Article history: Oxidative stress attributes a crucial role in chronic complication of diabetes. The aim of this Received 17 September 2014 study was to determine the most effective part of pomegranate on oxidative stress markers Received in revised form 13 October 2014 and antioxidant enzyme activities against streptozotocin-nicotinamide (STZ-NA)-induced Accepted 27 October 2014 diabetic rats. Male Sprague-Dawley rats were randomly divided into six groups.
    [Show full text]
  • Synthesis of a Coumarin-Based PPAR Fluorescence Probe for Competitive Binding Assay
    International Journal of Molecular Sciences Article Synthesis of a Coumarin-Based PPARγ Fluorescence Probe for Competitive Binding Assay Chisato Yoshikawa, Hiroaki Ishida , Nami Ohashi and Toshimasa Itoh * Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan; [email protected] (C.Y.); [email protected] (H.I.); [email protected] (N.O.) * Correspondence: [email protected] Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a molecular target of metabolic syndrome and inflammatory disease. PPARγ is an important nuclear receptor and numerous PPARγ ligands were developed to date; thus, efficient assay methods are important. Here, we investigated the incorporation of 7-diethylamino coumarin into the PPARγ agonist rosiglitazone and used the com- pound in a binding assay for PPARγ. PPARγ-ligand-incorporated 7-methoxycoumarin, 1, showed weak fluorescence intensity in a previous report. We synthesized PPARγ-ligand-incorporating coumarin, 2, in this report, and it enhanced the fluorescence intensity. The PPARγ ligand 2 main- tained the rosiglitazone activity. The obtained partial agonist 6 appeared to act through a novel mechanism. The fluorescence intensity of 2 and 6 increased by binding to the ligand binding domain (LBD) of PPARγ and the affinity of reported PPARγ ligands were evaluated using the probe. Keywords: PPARγ ligand; coumarin; fluorescent ligand; screening; crystal structure Citation: Yoshikawa, C.; Ishida, H.; Ohashi, N.; Itoh, T. Synthesis of a Coumarin-Based PPARγ 1. Introduction Fluorescence Probe for Competitive Binding Assay. Int. J. Mol. Sci. 2021, Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor su- 22, 4034.
    [Show full text]
  • Underactive Thyroid
    Underactive Thyroid PDF generated using the open source mwlib toolkit. See http://code.pediapress.com/ for more information. PDF generated at: Thu, 21 Jun 2012 14:27:58 UTC Contents Articles Thyroid 1 Hypothyroidism 14 Nutrition 22 B vitamins 47 Vitamin E 53 Iodine 60 Selenium 75 Omega-6 fatty acid 90 Borage 94 Tyrosine 97 Phytotherapy 103 Fucus vesiculosus 107 Commiphora wightii 110 Nori 112 Desiccated thyroid extract 116 References Article Sources and Contributors 121 Image Sources, Licenses and Contributors 124 Article Licenses License 126 Thyroid 1 Thyroid thyroid Thyroid and parathyroid. Latin glandula thyroidea [1] Gray's subject #272 1269 System Endocrine system Precursor Thyroid diverticulum (an extension of endoderm into 2nd Branchial arch) [2] MeSH Thyroid+Gland [3] Dorlands/Elsevier Thyroid gland The thyroid gland or simply, the thyroid /ˈθaɪrɔɪd/, in vertebrate anatomy, is one of the largest endocrine glands. The thyroid gland is found in the neck, below the thyroid cartilage (which forms the laryngeal prominence, or "Adam's apple"). The isthmus (the bridge between the two lobes of the thyroid) is located inferior to the cricoid cartilage. The thyroid gland controls how quickly the body uses energy, makes proteins, and controls how sensitive the body is to other hormones. It participates in these processes by producing thyroid hormones, the principal ones being triiodothyronine (T ) and thyroxine which can sometimes be referred to as tetraiodothyronine (T ). These hormones 3 4 regulate the rate of metabolism and affect the growth and rate of function of many other systems in the body. T and 3 T are synthesized from both iodine and tyrosine.
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • Regulation of Enac-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors
    Hindawi Publishing Corporation PPAR Research Volume 2010, Article ID 703735, 9 pages doi:10.1155/2010/703735 Review Article Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors Tengis S. Pavlov,1 John D. Imig,2, 3 and Alexander Staruschenko1, 4 1 Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 2 Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 3 Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA 4 Kidney Disease Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA Correspondence should be addressed to Alexander Staruschenko, [email protected] Received 6 January 2010; Revised 16 March 2010; Accepted 14 April 2010 Academic Editor: Tianxin Yang Copyright © 2010 Tengis S. Pavlov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Peroxisome proliferator-activated receptors (PPARs) are members of a steroid hormone receptor superfamily that responds to changes in lipid and glucose homeostasis. Peroxisomal proliferator-activated receptor subtype γ (PPARγ)hasreceivedmuch attention as the target for antidiabetic drugs, as well as its role in responding to endogenous compounds such as prostaglandin J2. However, thiazolidinediones (TZDs), the synthetic agonists of the PPARγ are tightly associated with fluid retention and edema, as potentially serious side effects. The epithelial sodium channel (ENaC) represents the rate limiting step for sodium absorption in the renal collecting duct. Consequently, ENaC is a central effector impacting systemic blood volume and pressure. The role of PPARγ agonists on ENaC activity remains controversial.
    [Show full text]
  • BIOINFORMATICS APPLICATIONS NOTE Doi:10.1093/Bioinformatics/Btu426
    Vol. 30 no. 20 2014, pages 2981–2982 BIOINFORMATICS APPLICATIONS NOTE doi:10.1093/bioinformatics/btu426 Structural bioinformatics Advance Access publication July 4, 2014 YASARA View—molecular graphics for all devices—from smartphones to workstations Elmar Krieger* and Gert Vriend Centre for Molecular and Biomolecular Informatics, NCMLS, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, the Netherlands Downloaded from https://academic.oup.com/bioinformatics/article-abstract/30/20/2981/2422272 by guest on 17 March 2019 Associate Editor: Janet Kelso ABSTRACT 2 METHODS Summary: Today’s graphics processing units (GPUs) compose the The general idea is very simple and has been used ever since texture scene from individual triangles. As about 320 triangles are needed to mapping became part of 3D graphics: if an object is too complex (like approximate a single sphere—an atom—in a convincing way, visualiz- the 960 triangles required to draw a single water molecule in Fig. 1A) it is ing larger proteins with atomic details requires tens of millions of tri- replaced with ‘impostors’, i.e. fewer triangles that have precalculated tex- angles, far too many for smooth interactive frame rates. We describe a tures attached, which make them look like the original object. Texture mapping means that a triangle is not rendered with a single color, but an new approach to solve this ‘molecular graphics problem’, which image (the texture) is attached to it instead. For each of the three triangle shares the work between GPU and multiple CPU cores, generates vertices, the programmer can specify the corresponding 2D coordinates in high-quality results with perfectly round spheres, shadows and ambi- the texture, and the hardware interpolates in between.
    [Show full text]
  • “One Ring to Rule Them All”
    OpenMM library “One ring to rule them all” https://simtk.org/home/openmm CHARMM * Abalone Presto * ACEMD NAMD * ADUN * Ascalaph Gromacs AMBER * COSMOS ??? HOOMD * Desmond * Culgi * ESPResSo Tinker * GROMOS * GULP * Hippo LAMMPS * Kalypso MD * LPMD * MacroModel * MDynaMix * MOLDY * Materials Studio * MOSCITO * ProtoMol The OpenM(olecular)M(echanics) API * RedMD * YASARA * ORAC https://simtk.org/home/openmm * XMD Goals of OpenMM l Complete library l provide what is most needed l easy to learn and use l Fast, general, extensible l optimize for speed l hide hardware specifics l support new hardware l add new force fields, integration methods etc. l Available APIs in C++, Fortran95, Python l Advantages l Object oriented l Modular l Extensible l Disadvantages l Programs written in other languages need to invoke it through a layer of C++ code Features • Electrostatics: cut-off, Ewald, PME • Implicit solvent • Integrators: Verlet, Langevin, Brownian, custom • Thermostat: Andersen • Barostat: MonteCarlo • Others: energy minimization, virtual sites 5 The OpenMM Architecture Public Interface OpenMM Public API Platform Independent Code OpenMM Implementation Layer Platform Abstraction Layer OpenMM Low Level API Computational Kernels CUDA/OpenCL/Brook/MPI etc. Public API Classes (1) l System l A collection of interaction particles l Defines the mass of each particle (needed for integration) l Specifies distance restraints l Contains a list of Force objects that define the interactions l OpenMMContext l Contains all state information for a particular simulation − Positions, velocities, other parmeters Public API Classes (2) l Force l Anything that affects the system's behavior: forces, barostats, thermostats, etc. l A Force may: − Apply forces to particles − Contribute to the potential energy − Define adjustable parameters − Modify positions, velocities, and parameters at the start of each time step l Existing Force subclasses − HarmonicBond, HarmonicAngle, PeriodicTorsion, RBTorsion, Nonbonded, GBSAOBC, AndersenThermostat, CMMotionRemover..
    [Show full text]
  • Pomegranate (Punica Granatum)
    Functional Foods in Health and Disease 2016; 6(12):769-787 Page 769 of 787 Research Article Open Access Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics Veljko Veljkovic1,2, Sanja Glisic2, Vladimir Perovic2, Nevena Veljkovic2, Garth L Nicolson3 1Biomed Protection, Galveston, TX, USA; 2Center for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, Serbia; 3Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA 92647 USA Corresponding author: Garth L Nicolson, PhD, MD (H), Department of Molecular Pathology, The Institute for Molecular Medicine, Huntington Beach, CA 92647 USA Submission Date: October 3, 2016, Accepted Date: December 18, 2016, Publication Date: December 30, 2016 Citation: Veljkovic V.V., Glisic S., Perovic V., Veljkovic N., Nicolson G.L.. Pomegranate (Punica granatum): a natural source for the development of therapeutic compositions of food supplements with anticancer activities based on electron acceptor molecular characteristics. Functional Foods in Health and Disease 2016; 6(12):769-787 ABSTRACT Background: Numerous in vitro and in vivo studies, in addition to clinical data, demonstrate that pomegranate juice can prevent or slow-down the progression of some types of cancers. Despite the well-documented effect of pomegranate ingredients on neoplastic changes, the molecular mechanism(s) underlying this phenomenon remains elusive. Methods: For the study of pomegranate ingredients the electron-ion interaction potential (EIIP) and the average quasi valence number (AQVN) were used. These molecular descriptors can be used to describe the long-range intermolecular interactions in biological systems and can identify substances with strong electron-acceptor properties.
    [Show full text]